---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000057"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:24:50.549064+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Halozyme stockholders elect directors, approve say-on-pay, ratify auditor

## Summary
- Directors Connaughton and Posard elected with 89.1M and 82.7M votes for, respectively.
- Advisory vote on executive compensation approved: 84.7M for, 9.3M against.
- Ratification of Ernst & Young as FY2026 auditor passed with 103.2M votes for.
- Over 104.1M of 118.5M outstanding shares were represented at the meeting.

## SEC filing metadata
- accession: 0001159036-26-000057
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/halo-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000057
- JSON: https://secwatch.observer/filing/0001159036-26-000057.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000057.txt

## Key facts
- Shareholder Votes
  HALOZYME THERAPEUTICS, INC. shareholders approved Ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-05 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-05-05
  source text: Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: Votes For Votes Against Abstain Broker Non-Votes 103,197,579 849,433 91,232 --- The foregoing proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm
- Shareholder Votes
  HALOZYME THERAPEUTICS, INC. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-05-05 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-05-05
  source text: Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 84,682,518 9,311,426 255,081 9,889,219 The foregoing proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm
- Shareholder Votes
  HALOZYME THERAPEUTICS, INC. shareholders approved Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2026-05-05 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-05-05
  source text: Proposal 1 : Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Bernadette Connaughton 89,053,734 5,068,160 127,131 9,889,219 Matthew L. Posard 82,739,433 10,236,878 1,272,714 9,889,219 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.